Using our Pept-inTM platform technology, we can create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.
Aelin Therapeutics is a privately held Belgian biotherapeutics company, pioneering a novel modality in drug development.
OUR INVESTORS
Building on a solid scientific base and a convincing data set, Aelin Therapeutics secured € 27M in a Series A financing, bringing together a strong group of well-reputed investors consisting of LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany) and Fund+ (Belgium).




OUR TEAM
MANAGEMENT


In 2006, he joined Ablynx, a Sanofi Company, where as a functional lead, he was contributing to the development and successful submission of Cablivi®. Concomitantly, he took various roles with increasing responsibilities leading to heading up the Pharmacology department.
In 2017, he joined UCB as head of the bioanalytical scientific management team, being accountable for the bioanalytical activities in the development portfolio. He contributed to the approval of Cimzia® for non-radiographic axial spondyloarthritis and Bimzelx® for the treatment of moderate to severe plaque psoriasis.
Dr Ulrichts holds a PhD degree in Biochemistry from the University of Leuven.







Before joining Aelin Therapeutics, Dr Scorneaux managed several programs and teams within Deinobiotics, Eyevensys, Scynexis, Enanta and the Swiss Tropical Institute.
Bernard Scorneaux holds a PhD in biology, pharmacokinetics and microbiology from the Université Catholique de Louvain, Brussels, Belgium.
BOARD






Frank is a physician by training did his PhD in Pharmacology and specialized in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin.
He began his industrial career at Schering AG and moved in 1999 to Boehringer Ingelheim joining Pulmonary Research. In 2005, he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization in various indication areas. In addition, he built up the Biological Research unit at the German Research site in Biberach.
In 2010 - shortly after its initiation - Frank joined the Boehringer Ingelheim Venture Fund.


SCIENTIFIC FOUNDERS AND ADVISORS
Aelin Therapeutics’ pipeline is based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau of the Switch lab.

They are currently group leaders at the KU Leuven-VIB Centre for Brain & Disease Research where they conduct research on mechanisms of protein misfolding and aggregation in disease. They developed several technology platforms manipulating protein aggregation either to inhibit protein aggregation or to design synthetic amyloid peptides with biological activity.

They are currently group leaders at the KU Leuven-VIB Centre for Brain & Disease Research where they conduct research on mechanisms of protein misfolding and aggregation in disease. They developed several technology platforms manipulating protein aggregation either to inhibit protein aggregation or to design synthetic amyloid peptides with biological activity.